The Problem With Waiting Most formulation vendors approach business development reactively. They wait for a drug to lose exclusivity, watch […]

There’s a quiet shift happening in pharmacology that doesn’t show up neatly in prescribing guidelines or FDA labels. It shows

The Number Nobody Puts in the Model Every pharma M&A deal starts with a revenue forecast. Bankers build complex discounted

Every pharmaceutical executive knows the word “patent cliff.” Fewer can accurately define the legal machinery underneath it. Fewer still understand

Why Your LOE Strategy Depends on Molecule Type A brand-name drug losing its final patent is not one event. It

Every year, billions of euros in pharmaceutical procurement value shifts from branded drug budgets to competitive tender processes across the

Methods-of-use patents have quietly become the pharmaceutical industry’s most underappreciated exclusivity tool. Here’s how they work, who’s using them, and

The Window You Cannot Miss Every drug patent that expires is a commercial event for at least a dozen industries.

The FDA lets you extend only one patent per drug approval. Most companies leave years of exclusivity on the table